Preclinical data suggest low toxicity, and short-term use appears well tolerated
Stable gastric pentadecapeptide BPC 157, Roberts stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selyes stress coping response: Progress, achievements, and future
Clinical observations reveal that patients with Graves disease who undergo our cell-based therapy within 3-4 weeks of diagnosis, upon qualification process, often exhibit the most favorable post-treatment outcomes
In: Parekattil SJ, Esteves SC, Agarwal A, editors
Reduce Sleep Disorder Improve Memory Enhance Concentration Boost Energy Levels Mood Elevation Maintain Fertility Reduce Fatigue Concentration: 5mg/ml | Route of Administration: IV/IM